[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100597583":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":20,"locations":26,"responsibleParty":42,"collaborators":11,"id":46,"slug":47,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":11,"eligibilityCriteria":51,"healthyVolunteers":48,"sex":52,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":11,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":65,"overallStatus":28,"whyStopped":11,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"Shanghai Chest Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Contrast-Enhanced Endobronchial Ultrasound","EXPERIMENTAL",null,[13],"Device: Contrast-enhanced endobronchial ultrasound",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"DEVICE","Contrast-enhanced endobronchial ultrasound","Using CE-EBUS to observe pulmonary lesions and abnormal enlarged intrathoracic lymph nodes, the enhancement characteristics of benign and malignant lesions under CE-EBUS were extracted for both conditions.",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":11,"email":25},"Jiayuan sun","CONTACT","+1511 86-021-22200000","jysun1976@163.com",[27],{"facility":5,"status":28,"city":29,"state":30,"zip":11,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"RECRUITING","Shanghai","Shanghai Municipality","China","CN",{"type":34,"coordinates":35},"Point",[36,37],121.45806,31.22222,{"lat":37,"lon":36},[40],{"name":41,"role":23,"phone":24,"phoneExt":11,"email":25},"jiayuan sun",{"type":43,"investigatorFullName":44,"investigatorTitle":45,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Jiayuan Sun","Vice-President of the hospital","100597583","a-study-of-contrast-enhanced-ebus-in-lung-lesions-and-intrathoracic-lymph-nodes-100597583",false,"NCT07060378","A Study of Contrast-enhanced EBUS in Lung Lesions and Intrathoracic Lymph Nodes","Inclusion Criteria:\n\n* Age \\>18 years old；\n* Enlargement of at least one intrathoracic LN (short diameter \\> 1 cm) or central parenchymal lung lesions adjacent to the airway detected on chest CT, or increased fluorodeoxyglucose uptake in at least one intrathoracic lymph node on PET \u002F CT (standardized uptake value \\> 2.5)；\n* CP-EBUS-TBNA is required to determine the diagnosis or staging, the patient agreed to undergo CE-EBUS, and there were no contraindications to EBUS-TBNA;\n* Patients who have good compliance and sign informed consent.\n\nExclusion Criteria:\n\n* Patients with known hypersensitivity to ultrasound contrast components;\n* Patients with severe pulmonary hypertension (pulmonary artery pressure \\> 90 mmHg);\n* Patients with angina pectoris, acute coronary syndrome, clinically unstable ischemic heart disease, heart failure, cardiac dysfunction, and cardiac disease with right-to-left shunting;\n* Patients with uncontrolled essential hypertension and adults with respiratory distress syndrome;\n* Pregnant or lactating women；\n* Patients with contraindications to bronchoscopy；\n* Patients with other conditions that, in the opinion of the investigator, make the patient unsuitable for the study.","ALL","18 Years","90 Years",{"count":56,"type":57},250,"ESTIMATED","INTERVENTIONAL",[60],"NA","Exploring the Clinical Application Value of Contrast Enhancement Features in CE-EBUS Images for the Diagnosis of Pulmonary Lesions and Intrapulmonary Lymph Nodes",[63,64],"Lung Lesions","Mediastinal and Hilar Lymph Node Enlargement",[66,67,68],"CE-EBUS","Ultrasound Contrast Agent","Microbubbles","2025-07-10",{"date":71,"type":72},"2025-07-11","ACTUAL",{"date":69,"type":72},{"date":75,"type":57},"2026-01-30",{"name":5,"class":6},1]